FDA grants priority review for Dupixent (dupilumab) in COPD with type 2 inflammation, with positive Phase 3 trial results.
FDA grants priority review for Dupixent (dupilumab) in COPD with type 2 inflammation. Positive results from two Phase 3 trials support the application, and if approved, Dupixent would be the first biologic therapy for COPD and the first new treatment approach for the disease in over a decade. Regulatory submissions are also under review in China and Europe.
February 23, 2024
11 Articles